uniQure N.V. (QURE) Earnings Call Analysis

NASDAQ · Unknown · Unknown

10/25

Growth 2 Margin 2 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
Unicure (QURE) Q2 2026: $188M Cash Infusion Extends Runway as AMT-130 BLA Nears Submission
July 29, 2026
9
Unicure (QURE) Q1 2026: $6.9M R&D Cut Reflects Pipeline Discipline as UK Regulatory Pathway Accelerates
June 17, 2026
9
Unicure (QURE) Q3 2025: 75% Disease Progression Slowdown in Huntington’s Data Faces FDA Roadblock
June 16, 2026
9
Unicure (QURE) Q4 2025: $404M Raise Extends Runway as FDA Demands Phase 3 Sham-Controlled Study
June 15, 2026
8
Unicure (QURE) Q2 2025: $377M Cash Extends Runway as AMT-130 Nears September Data Catalyst
July 29, 2025
10
Unicure (QURE) Q1 2025: Cash Position Surges to $409M as AMT-130 Nears Regulatory Milestone
July 07, 2025

Browse all companies